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RNAmolecules perform diverse regulatory functions in natural bio-
logical systems, and numerous synthetic RNA-based control devices
that integrate sensing and gene-regulatory functions have been
demonstrated, predominantly in bacteria and yeast. Despite poten-
tial advantages of RNA-based genetic control strategies in clinical
applications, there has been limited success in extending engi-
neered RNA devices to mammalian gene-expression control and
no example of their application to functional response regulation
in mammalian systems. Here we describe a synthetic RNA-based
regulatory system and its application in advancing cellular thera-
pies by linking rationally designed, drug-responsive, ribozyme-
based regulatory devices to growth cytokine targets to control
mouse and primary human T-cell proliferation. We further demon-
strate the ability of our synthetic controllers to effectively modu-
late T-cell growth rate in response to drug input in vivo. Our RNA-
based regulatory system exhibits unique properties critical for
translation to therapeutic applications, including adaptability to di-
verse ligand inputs and regulatory targets, tunable regulatory
stringency, and rapid response to input availability. By providing
tight gene-expression control with customizable ligand inputs,
RNA-based regulatory systems can greatly improve cellular thera-
pies and advance broad applications in health and medicine.
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The ability to control functional responses in mammalian cellswith customizable and compact regulatory systems in vivo ad-
dresses a critical need in diverse clinical applications, particularly
in cellular therapies (1). As an example, adoptive T-cell therapy
seeks to harness the precision and efficacy of the immune system
against diseases that escape the body’s natural surveillance. The
adoptive transfer of antigen-specific T cells can reconstitute
immunity to viruses and mediate tumor regression (2–4). T cells
engineered to express tumor-specific T-cell antigen receptors can
achieve highly refined target recognition (5), thus minimizing
toxic off-target effects associated with conventional chemother-
apy. However, considerable research has shown that the persis-
tence of transferred T cells in vivo is both central to therapeutic
success and elusive to current technology (6, 7). The efficacy of
adoptive immunotherapy in humans is often limited by the failure
of transferred T cells to survive in the host (8, 9).
Clonal expansion of T cells is a critical component of T-cell
activation mediated by cytokines such as IL-2 and IL-15, which
activate JAK-STAT signaling pathways and lead to the expres-
sion of genes involved in growth modulation (10) (Fig. 1A). Sus-
taining the survival and proliferation of Tcells following adoptive
transfer is challenging because of the limited availability of
homeostatic cytokines (IL-15/IL-7) and stimulatory antigen pre-
senting cells. State-of-the-art strategies for improving the persis-
tence of adoptively transferred lymphocytes require that patients
be subjected to myeloablative total body irradiation/chemother-
apy and toxic levels of IL-2 (11). Alternative strategies with un-
regulated expression of growth-related genes pose the risk of
uncontrolled lymphoproliferation and leukemic transformation
(6). Thus, the ability to integrate growth-stimulatory gene expres-
sion with tightly controlled regulatory systems has the potential to
greatly improve the safety and efficacy of adoptive T-cell therapy.
Inspired by the diverse functional roles exhibited by regulatory
RNAs in natural systems (12–14) and the relative ease by which
RNA can be modeled and designed (15), researchers have begun
developing synthetic RNA-based regulatory systems that inte-
grate discrete gene-regulatory and sensing functions as genetic
control strategies (16–18). However, the absence of successful
adaptations of these earlier genetic devices to the regulation
of functional responses in mammalian cells highlights remaining
difficulties in translating designs that regulate reporter gene ex-
pression to functional control.
We describe a synthetic, small-molecule-responsive RNA-
based gene-regulatory system in mammalian cells and demon-
strate its application in advancing cell-based therapies through the
control of cell-fate decisions. We develop a genetic strategy for
effectively controlling T-cell expansion on the basis of drug-
responsive RNA regulators that exert tight control over key up-
stream signalingmolecules in the proliferation pathway. Our work
demonstrates aRNA-based regulatory system that exhibits unique
properties critical for translation to therapeutic applications, in-
cluding adaptability to diverse inputmolecules and genetic targets,
tunable regulatory stringency, and rapid input response.
Results
A RNA-Based System Enables Gene Expression and Viability Control in
T Cells. We developed a RNA-based regulatory system for mam-
malian T-cell proliferation on a platform for assembling RNA de-
vices from modular sensor (aptamer) and gene-regulatory
(hammerhead ribozyme) components. The activity of this ribo-
zyme switch platform had been shown in the microorganism Sac-
charomyces cerevisiae (19, 20); however, the activity of these
genetic regulatory elements in mammalian cells had not been
previously examined.
Cytokines are potent growth-stimulatory molecules whose ef-
fects on cell growth are amplified through the JAK-STAT signal-
ing pathway (Fig. 1A). The ability to regulate upstream pathway
molecules and take advantage of signal amplification through an
endogenous pathway toward downstream functional responses is
an important design strategy supported by our RNA regulatory
system. We developed a cell-intrinsic control system for cytokine
production utilizing ribozyme ON switches, which are RNA
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devices that convert a small-molecule input to an increased gene-
expression output (Fig. 1B). The system design ensures suppres-
sion of cell growth as a default state and induction of cell prolif-
eration only in the presence of an administered small-molecule
drug input. In this system, the ribozyme-based device is placed in
the 3′ UTR of a target transgene encoding a proliferative cyto-
kine, where self-cleavage by the ribozyme results in rapid degra-
dation of the target transcript and decreased cytokine production.
The ribozyme device is designed to adopt at least two conforma-
tions (input-unbound and input-bound) associated with either a
ribozyme-active or -inactive state. The presence of drug input sta-
bilizes the input-bound, ribozyme-inactive conformation, thereby
preserving transcript integrity and up-regulating cytokine produc-
tion, resulting in autocrine cell growth. The absence of drug input
stabilizes the ribozyme-active conformation, resulting in tran-
script degradation, reduced cytokine production, and diminished
cell growth.
As a model system, a fusion transgene encoding a proliferative
cytokine (IL-2) and a quantifiable protein marker (EGFP) served
as the regulatory target to permit simultaneous quantification of
the regulatory system’s performance at the levels of direct gene
expression (fluorescence) and downstream pathway output (via-
bility) (Fig. 2A). The cytokine and reporter proteins were linked
through a self-cleaving T2A peptide (SI Text) to ensure that the
ribozyme switch activity was equally effective on the linked target
genes but that the proteins fold and function as independent mo-
lecules. Three theophylline (theo)-responsive ribozyme switches
(L2bulge1, 8, and 9; SI Text), which had been tuned through se-
quence modifications to exhibit different regulatory response
properties (19), were inserted into the 3′ UTR of the egfp-t2a-
il2 fusion gene. Plasmids incorporating this regulatory system
were transiently transfected into the CTLL-2 mouse T-cell line,
which, like primary human T cells, is dependent on common γ-
chain signaling for survival and proliferation (21). Each of the
ribozyme switches resulted in input-responsive regulation over
cell viability and fluorescence (Fig. 2B and Fig. S1A; see SI Text
for a discussion on controls and normalization methods), con-
firming the prescribed function of these devices in mammalian
cells. The ribozyme-based regulatory systems provided titratable
response over a range of input concentrations (Fig. 2C and
Fig. S1B), demonstrating the ability to adjust expression levels
on the basis of input availability.
A General Strategy for Tuning the Dynamic Range of Ribozyme
Switches Allows for Modulation of T-Cell Proliferation Response.
The potency of the genetic targets in our T-cell regulatory system
requires stringent control over basal cytokine expression levels,
such that in the absence of input the engineered T cells exhibit
proliferation levels similar to cells growing in the absence of cy-
tokine. To engineer a more stringent regulatory system, we imple-
mented a second tuning strategy by linking multiple copies of the
ribozyme switches in the 3′UTRof the transgene. Only one of the
switches needs to be in a ribozyme-active state to inactivate the
transcript. Therefore, multiple-copy switch devices increase the
probability of transcript cleavage and lower basal expression le-
vels (20). We developed a construction strategy for sequentially
inserting ribozyme switches in the 3′ UTR of the transgene and
insulated the switches through spacer sequences designed to
maintain the structural integrity and functional independence
of each switch (SI Text and Fig. 2A).
Characterization studies indicated that this tuning strategy ef-
fectively decreased basal expression levels (Fig. 2B and Fig. S1A)
and that the titratable response of the system was maintained
(Fig. 2C and Fig. S1B). Stringent knockdown was achieved with
three and four copies of the tightest switch (L2bulge9; Fig. 2B),
which resulted in viability levels comparable to cells transfected
with no cytokine or with the fully active, nonswitch ribozyme (no
IL-2 control and sTRSV ribozyme, respectively). Notably, the
regulatory performance of the four-copy switch system was simi-
lar to that of the three-copy system (Fig. 2B), indicating that three
copies of the tightest switch were sufficient to approach the mini-
mum possible viability levels. The data underscore the nonlinear
relationship between direct gene expression and functional path-
way outputs from the system. Whereas absolute changes in gene
expression (fluorescence) in response to drug input remain simi-
lar for constructs with varying copies of a ribozyme switch
(Fig. S1A), the absolute changes in pathway output (viability) in-
creased substantially with ribozyme copy number (Fig. 2B).
Ribozyme Switches Can Be Programmed to Respond to Alternative
Drug Molecules. The on-state expression levels of drug-responsive
RNA regulatory systems can be limited by the toxicity and cell per-
meability of the input molecule (22). However, the ribozyme-
based regulatory system’s component functions are modular
and thus amenable to changes that support customization for di-
verse applications, such as reprogramming input responsiveness
Fig. 1. An engineered T-cell proliferation regulatory system utilizing a synthetic RNA device to achieve drug-mediated modulation of cell signaling and
proliferation. (A) The common γ-chain T-cell proliferation pathway and integration of a synthetic controller targeted to the upstream signaling events.
(B) An engineered T-cell proliferation regulatory system on the basis of programmable drug-mediated regulation of cytokine expression from a synthetic
ribozyme switch. Ribozyme color scheme is as described in ref. 19.
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toward clinically usable pharmaceuticals. To verify this critical
property of our prototype T-cell proliferation control system,
we replaced the theo aptamer (23) with the tetracycline (tet) ap-
tamer (24) to construct a tet-responsive switch (L2bulge18tc;
Fig. 2D). In vitro assays demonstrated tet-responsive ON switch
activity in CTLL-2 cells (Fig. 2E). The tet-responsive systems de-
monstrated lower basal expression levels and increased dynamic
ranges in response to lower input concentrations relative to the
theo-responsive systems. Although tet is not a clinically applicable
drug input, the tet switch system demonstrates the ability to im-
prove regulatory stringency and increase the switch dynamic range
by using aptamers with higher affinities and input molecules that
can be administered to higher intracellular concentrations.
A Clinically Relevant T-Cell Proliferation System with Drug-Modulated
Regulation of IL-15 Levels.Although IL-2 plays a critical role in the
stimulation of activated T cells, it is also involved in activation-
induced cell death and the establishment of peripheral tolerance.
Several studies have indicated that an alternative γ-chain cyto-
kine, IL-15, provides potent homeostatic T-cell survival/prolifera-
tive signals, inhibits IL-2-mediated activation-induced cell death,
and may be superior to IL-2 in immunotherapy applications (25,
26). Recently, IL-15 has been shown to function in establishing
the long-term persistence of adoptively transferred central mem-
ory T (TCM) cells in primates, suggesting significant potential in
T-cell therapy for cancer (27). To develop a more clinically rele-
vant regulatory system, we utilized the modularity of the ribozyme
switch platform and replaced the egfp-t2a-il2 transgene with a tri-
functional fusion transgene (cd19-tk-t2a-il15) encoding IL-15,
mutant HSV-1 thymidine kinase (ser39TK, a protein marker that
can act as a PETreporter and as a suicide protein in the presence
of the drug ganciclovir, providing imaging and safety kill-switch
Fig. 2. Modularly constructed ribo-
zyme switches exhibit tunable, drug-
mediated regulation of gene expres-
sion and cell growth in mammalian
T cells. (A) A modular insertion strat-
egy allows the implementation of
multiple copies of ribozyme switches
to tune regulatory stringency. Spacer
sequences (Orange and Green) pro-
vide structural insulation and main-
tain the functional independence
of each switch. (B) Ribozyme switches
provide tunable, small-molecule-
mediated regulatory systems. Cell via-
bility levels are reported for constructs
encoding theo-responsive switches
(L2bulge1, 8, 9) in one (1×), two
(2×), three (3×), and four (4×) copies
through transient transfections in
CTLL-2 cells grown in 0 and 1 mM
theo. No IL-2 control, construct not en-
coding a proliferative cytokine; sTRSV
ribozyme, construct encoding a non-
switch hammerhead ribozyme. The
gray bar indicates background viabili-
ty level of cells in the absence of cyto-
kine. (C) Ribozyme switches provide
titratable regulatory systems. Cell
viability levels are reported for the
L2bulge9 regulatory systems at vari-
ous theo concentrations. (D and E)
Tailoring of the input responsiveness
of the RNA-based regulatory system
through direct replacement of the
sensor component generates titrata-
ble, tet-responsive switches (L2bul-
ge18tc). (F and G) Tailoring of the
output of the RNA-based regulatory
system through direct replacement
of the target gene (cd19-tk-t2a-il15)
achieves enhanced survival response
compared to IL-2-based systems. All
viability and fluorescence values were
normalized to those of controls ex-
pressing the appropriate transgene
regulated by an inactive ribozyme
and cultured at corresponding theo
concentrations. Reported values are
mean SD from at least two replicate
samples.
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functionalities for downstream clinical implementations), and
CD19 (a quantifiable protein marker amenable to FACS- and
immunomagnetic-based selections). The alternative transgene
was placed directly into the theo-responsive switch systems with
L2bulge9 (Fig. 2F). The modified system exhibited ON switch
control over cell viability and proliferation in transient transfec-
tion experiments (Fig. 2G), confirming modular coupling be-
tween the target transgene and the regulatory device. Samples
expressing IL-15 showed higher viability levels compared to those
expressing IL-2 with the corresponding switch systems (Fig. 2 C
and G), suggesting that IL-15 may be a more potent survival/pro-
liferative cytokine and can better amplify the signal response.
Therefore, under a low basal expression level, a small increase
in IL-15 expression has the potential to significantly enhance
T-cell proliferation.
Ribozyme Switches Enable Long-Term, Dynamic Control over Gene
Expression.We generated a CTLL-2 cell line (CffLuc) that stably
expressed the firefly luciferase (ffluc) gene to enable biophotonic
imaging of cell populations in vivo and subsequently integrated T-
cell proliferation regulatory systems with one or three copies of
L2bulge9 into CffLuc. Stable integrants were initially sorted on
the basis of CD19 expression, and bulk-sorted populations de-
monstrated theo-reponsive ON switch activity (Fig. S2). We
further refined the sorted population by alternating treatment
with ganciclovir and IL-2 or with theo and no IL-2 (Fig. S3)
to enrich for clones with low basal expression levels and suffi-
ciently high on-state expression levels to sustain cell survival, re-
spectively. We generated clonal cell lines by a final sorting step for
CD19-positive cells in the presence of theo.
Growth behavior of individual clones was characterized by cul-
turing under various theo concentrations. Results indicate that
the T-cell proliferation regulatory system retained functionality
over long time periods when stably integrated and that theo
effectively replaced IL-2 as the trigger for cell proliferation
(Fig. 3A). Fifteen of the sixteen clones examined showed substan-
tial theo-responsive increase in cell growth (Fig. S4), supporting
that the growth modulation effect is specific to the introduced
regulatory system.
Additional assays on a clonal cell line harboring three copies of
L2bulge9 (clone 1264-48) were performed to verify the mechan-
ism of growth regulation and examine the dynamic behavior of
the regulatory system to variations in theo availability. Cell cul-
tures were grown for one week in the presence of 500 μM theo
and continued for a second week in the absence of theo. Theo was
reintroduced for another four days at the end of the study. Re-
sults indicated rapid (within 24 hours of induction), sustained,
and reversible regulation of CD19 protein levels in response
to theo (Fig. 3B). IL-15 expression patterns were verified at
the transcript level through qRT-PCR (Fig. S5A). In addition,
Western blot analysis of phosphorylated STAT5 levels verified ac-
tivation of the IL-15 receptor-signaling cascade in the presence of
theo (Fig. S5B). These results highlight the ability of the ribozyme
switch system to quickly, effectively, and robustly switch gene ex-
pression on and off in response to drug input.
Ribozyme Switches Enable Drug-Modulated Control over T-Cell Prolif-
eration in Vivo.To verify in vivo functionality, we examined several
clonal cell lines for theo-dependent growth in mice. Select clones
were encased in a hydrogel matrix that contained either 0 or
500 μM theo and injected into the flanks of NOD∕SCID-γ−∕−c
mice. Cell lines lacking the transgene regulatory system or stably
expressing the inactive ribozyme construct served as negative and
positive controls, respectively. In vivo T-cell expansion was not
observed from clones lacking cytokine expression (no IL-15 con-
trol, Fig. 4A), demonstrating the need for cytokine expression in
sustaining cell growth. Uncontrolled T-cell proliferation was ob-
served in the absence of a functional ribozyme-based regulatory
device regardless of theo availability (inactive Rz control,
Fig. 4A). In contrast, the clonal cell line 1264-48, which harbors
three copies of L2bulge9, showed a significantly stronger reporter
signal at the conclusion of the 14-day study when injected with
500 μM theo compared to the same clone injected without theo
[L2bulge9(3×), Fig. 4A]. Growth rate calculations on the basis of
flux measurements over the 14-day period indicated a 32% in-
crease in in vivo growth rate in the presence of 500 μM theo, lead-
ing to a 14-fold increase in luciferase signal (Fig. 4B and Fig. S6).
The in vivo study was repeated for clone 1264-48 with replicates,
with the inactive ribozyme serving as the positive control. Flux
measurements over a 9-day period indicated an average of
40% increase in the growth rate of clone 1264-48 in the presence
of 500 μM theo (n1 ¼ 4, n2 ¼ 6, P ¼ 0.038 by Mann–Whitney U
test). In contrast, the positive control did not show statistically
significant changes in growth rate (n1 ¼ 6, n2 ¼ 6, P ¼ 0.394;
Figs. S6C and S7), indicating that the input-responsive growth
behavior observed in clone 1264-48 was not because of nonspe-
cific effects of theo.
Ribozyme Switches Enable Proliferation Control in Primary Human T
Cells. To demonstrate the portability of the regulatory system to
A B
Fig. 3. T cells stably expressing ribozyme switch systems exhibit drug-mediated regulation of growth over extended time periods in vitro. (A) Clonal cell lines
stably expressing the ribozyme switch system exhibit drug-mediated growth. Cell growth was monitored by counting viable cells, and data for a representative
clone [1264-48, expressing cd19-tk-t2a-il15-L2bulge9(3×)] are shown. (B) The ribozyme switch system regulates gene expression in response to changes in input
concentrations. Duplicate sets of the clonal cell line 1264-48 were cultured in the presence (Red and Orange) and absence (Light Blue and Dark Blue) of theo
over 18 days. Expression levels were monitored by staining with PE-CD19 antibody, and values were normalized to those from the inactive ribozyme control.
The highest expression level was set to 100%. The red dashed line indicates background staining level of a cell line without a CD19 construct.
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human T lymphocytes and translatability to clinical applications,
we transduced primary human TCM cells with lentiviral vectors
encoding the cd19-tk-t2a-il15 transgene coupled to three copies
of the L2bulge9 switch or to an inactive ribozyme. Because a short
production timeline and streamlined processing are critical in
clinical applications, studies were performed on bulk transduced,
unsorted TCM populations to examine the robustness of the reg-
ulatory system under no population refinement. Transduced cells
were cultured in the presence and absence of 500 μM theo for five
days. Cells expressing L2bulge9 showed up to 15% increase in
CD19 expression levels (Fig. 5A), 24% increase in the live cell
population (Fig. 5B), and 54% reduction in the apoptotic cell po-
pulation (Fig. 5C) in the presence of theo compared to the inac-
tive ribozyme control, indicating drug-responsive ON switch
behavior in gene expression and cell growth. The measured
change in CD19 expression is comparable to that observed in
CTLL-2 stable cell lines (Fig. S2), and the shift in population dis-
tribution between live and apoptotic cells supports that the reg-
ulatory system is effective in controlling the fate of primary
human TCM cells.
Discussion
Achieving robust, controlled, long-term persistence of transfused
T cells in vivo is a critical objective in adoptive immunotherapy,
where efficacy depends on prolonged T-cell survival and safety
demands stringent growth regulation. The T-cell proliferation
challenge highlights a broader need for programmable regulatory
systems that can modulate functional responses in mammalian
cells. Whereas numerous gene-regulatory systems have been
developed, successful translation to clinical settings has been
limited. For example, synthetic inducible promoters require vari-
ous transcriptional regulatory proteins, thus requiring multiple
vectors and transgene expression systems. However, the stable
expression of multiple transgenes in primary cell lines presents
a significant challenge. In addition, concerns for potential immu-
nogenicity of heterologous proteins limits the use of inducible
promoters in clinical settings. Finally, the input specificity and
regulatory dynamic range of such protein-based systems are re-
latively difficult to reprogram, thus limiting the flexibility and
broader application of these systems.
An alternative technology that has been pursued with noted
success in the context of hematopoietic cell growth regulation is
based on chemical inducers of dimerization (CIDs), which induce
dimerization of pathway components fused to CID-binding do-
mains (28, 29). However, studies conducted with CID-based sys-
tems have required lethally irradiated animal subjects to allow
expansion of the transfused Tcells with the assistance of homeo-
static proliferation. In addition, this system is limited to the reg-
ulation of homodimerization events, a mechanism that does not
apply to many pathways of interest, including the common γ-
chain signaling pathway central to T-cell persistence. The CID-
based system is also fixed with respect to the input molecule,
which is not available as a pharmaceutical drug.
Our synthetic, drug-responsive RNA-based regulatory system
features properties that address critical limitations in existing
genetic control strategies for clinical applications, including
encapsulation within a compact, RNA-only platform (to avoid
the use of immunogenic protein-based components) and allowing
direct replacement of sensor and target transgene components
(to tailor the technology to diverse applications). Our work de-
scribes the successful translation of a RNA device to the regula-
tion of a functional response in mammalian cells. The unique
capability to program the regulatory device’s response properties
was key to the effective transition from reporter gene-expression
regulation to functional control. By developing a rational tuning
strategy for the regulatory stringency of our control system and
integrating our synthetic controller with upstream signaling com-
ponents, we were able to substantially enhance control over the
functional system response. Furthermore, the observed nonlinear
relationship between direct gene-expression levels and down-
stream pathway outputs highlights the importance of system de-
sign strategies. In particular, the ability to link synthetic
controllers with relatively moderate gene-regulatory activities
to potent upstream pathway components enables dramatic altera-
tions in downstream functional behaviors.
Another unique property of our RNA-based control system is
the modularity of the device framework, which supports rapid
and effective tailoring of the regulatory system to respond to
clinically applicable inputs. Furthermore, the implementation of
higher-order information processing devices (20) on platforms
that integrate multiple aptamers to both endogenous and exogen-
ous inputs will enable more sophisticated control strategies with
applications in autonomous control systems, in vivo diagnosis,
and precise localization of cellular therapeutics to disease targets.
The development of RNA aptamers to pharmaceuticals with
minimal off-target toxicities and high cell permeability and bio-
availability will be critical for the translation of these RNA-based
regulatory systems to clinical applications. Therefore, the cou-
pling of our modular device framework with advances in aptamer
selection processes (30) will more broadly support the tailoring of
RNA-based regulatory systems to diverse applications in health
A B
Fig. 4. T cells stably expressing the ribozyme switch
systems exhibit drug-mediated regulation of growth
over extended time periods in vivo. (A) Both cyto-
kine expression and functional ribozyme switches
are required for effective regulation of T-cell prolif-
eration. Images are shown for day 14 postinjection
of the negative control (no IL-15 Control, CffLuc), po-
sitive control (inactive Rz control, stable cell line ex-
pressing inactive ribozyme), and stable cell line
expressing the ribozyme switch system [L2bulge9
(3×), clone 1264-48] in the presence and absence
of 500 μM theo. (B) Total luciferase signal flux over
14 days after injection of T cells is reported from
the negative control (CffLuc) and clone 1264-48
[L2bulge9(3×)].
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and medicine, including diagnostics, cellular therapeutics, gene
therapy, and intelligent molecular therapies.
Materials and Methods
Mammalian Cell Culture Maintenance. The mouse T-cell line CTLL-2 was
obtained from ATCC and maintained in RPMI-1640 media (Lonza) supple-
mented with 10% heat-inactivated fetal bovine serum (Hyclone), 2 mM
sodium pyruvate (Gibco), and 4.5 g∕L D-(-)-glucose (Sigma). Cells were fed
100 U∕mL IL-2 every 48 hours and maintained between 0.05 × 106 and
0.50 × 106 cells∕mL. All cell lines stably expressing the ffLuc:zeocin fusion
gene were cultured with 0.20 mg∕mL zeocin (Invivogen). Primary human
TCM cells were derived from peripheral blood mononuclear cells (SI Text)
and maintained in RPMI-1640 media supplemented with 10% heat-
inactivated fetal bovine serum. Cells were fed 50 U∕mL IL-2 and 0.5 ng∕mL
IL-15 every 48 hours and maintained between 0.2 × 106 and
1.0 × 106 cells∕mL.
Transient Transfection and Fluorescence Quantification. All transient trans-
fections were performed with an Amaxa Nucleofector II and the Mouse T Cell
Nucleofector Kit (Amaxa). Appropriate concentrations of drug input were
added immediately after electroporation. Fluorescence and cell viability data
were obtained 24 and 48 hours after transfection, respectively, by using a
Quanta Cell Lab Flow Cytometer (Beckman Coulter). Plasmid maps are pro-
vided in Fig. S8. See SI Text and Fig. S9 for additional details.
In Vivo T-Cell Proliferation Studies in NOD/SCID-IL2(ko) Mice. Clonal cell lines
were expanded under regular culture conditions, washed, and resuspended
in PBS. A 100-μL solution containing 0.1 × 106 cells, 50% vol∕vol Matrigel (BD
Biosciences), and either 0 or 500 μM theo was injected subcutaneously into
the flank of NOD/scid-IL2(ko) mice. In vivo growth of the injected cells was
monitored by biophotonic imaging using the IVIS Imaging System 100 Series
(Xenogen). See SI Text for additional details.
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A B C
Fig. 5. The ribozyme switch system effectively regulates gene expression and cell fate in primary human TCM cells. (A) CD19 expression levels are elevated in
the presence of theo. The populations of cells that are (B) live and CD19þ or (C) apoptotic and CD19þ indicate an increase in live cells and decrease in apoptotic
cells in response to theo. Values for the L2bulge9(3×) sample are normalized to those of the inactive ribozyme control cultured at the same theo concentration.
Reported values are mean SD from triplicate samples. The highest level is set to 100%.
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